![real siemens step 7 -0 real siemens step 7 -0](https://wiki.ibhsoftec.com/en/images/7/72/Image018.jpg)
Quantitative detection may be useful to assist interpretation of COVID-19 immunity and to evaluate active immunization. Recently, quantitative serologic assays for measuring antibodies against the receptor binding domain (RBD) of the S protein have been developed. Several studies have already compared some of these assays and found acceptable concordance. Most serologic assays are qualitative and use either nucleocapsid (N) or spike (S) SARS-CoV-2 protein as the target for antibody detection.
![real siemens step 7 -0 real siemens step 7 -0](https://5.imimg.com/data5/CD/QM/MY-47649575/siemens-software-step7-basic-500x500.jpg)
To date, many SARS-CoV-2 antibody assays have been developed with different antigen targets and assay formats. Accurate antibody measurements support uncertain identification or evaluation in the case of resolved infection and can be useful for contact tracing and epidemiologic studies. Further standardization and harmonization of immunoassays might be helpful in monitoring immune status after COVID-19 infection or vaccination.Ĭoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic and presents a major health concern across the globe. SARS-CoV-2 S protein antibody levels as assessed by the CLIAs were not interchangeable, but showed reliable performance for predicting sVNT results. CLIAs had good performance in predicting sVNT positivity (Area Under the Curve (AUC), 0.959–0.987), with Abbott having the highest AUC value ( p < 0.05). However, Passing–Bablok regression analysis showed significant proportional differences between assays and converting results to binding antibody units (BAU)/mL still showed substantial bias. Antibody levels from the three CLIAs were correlated (r = 0.763–0.885). When we assessed time-course antibody levels, the Abbott and Siemens assays showed higher levels in patients with severe disease ( p < 0.05). All assays detected >90% of samples collected 14 days after symptom onset (Abbott 97.4%, Roche 96.2%, Siemens 92.3%, and GenScript 96.2%), and overall agreement among the four assays was 91.1% to 96.3%. We compared the results of three chemiluminescent immunoassays (CLIAs) (Abbott, Roche, Siemens) and a surrogate virus neutralization test (sVNT, GenScript) using 191 sequential samples from 32 COVID-19 patients. Quantitative SARS-CoV-2 antibody assays against the spike (S) protein are useful for monitoring immune response after infection or vaccination.